Cowen Group Stock News

Cepton (Nsdaq: CPTN) announces its participation in Cowen’s 2nd Annual Mobility Disruption Conference & Berenberg Industrial Technologies Conference

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a novel immuno-oncology panel discussion at the Cowen & Co. 42 nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.

NEW YORK , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced that Brian Hagerty has joined the company’s Equity Capital Markets team as

ESEA, OMVJF, and CROX made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 28, 2022

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to participate virtually in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7 from 9:10 AM – 9:40 AM ET.

Cowen (COWN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CCS, COWN, and VIST made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2022

CCS, COWN, and VIST made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2022

CARLSBAD, Calif., Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that TYRA management will be

This payroll services provider is more than meets the eye. Is now the time to buy?

A recall of certain infant formula powders made by Abbott Laboratories (ABT) could cost the company $325M in annual revenue, according to Cowen.

While Goldman (GS) increases medium-term firmwide return on equity target to 14-16% from the previous 13%, the transaction banking revenue target has been decreased to $750 million.

The mean of analysts' price targets for Cowen (COWN) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i

The mean of analysts' price targets for Cowen (COWN) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts i